Spirea
John Hartley is a distinguished Professor of Cancer Studies at UCL, where John has served since 1988. In addition to leading the UCL Experimental Cancer Medicine Centre and the UCL ECMC GCLP Facility, John Hartley co-directs the CRUK Drug-DNA Interactions Research Group. Hartley's industry experience includes advising for ADC Therapeutics from 2012 until January 2024 and serving as a Scientific Co-Founder of Spirogen Ltd from 2000 to January 2020, a company that became part of the AstraZeneca Group following its acquisition in 2013. John Hartley's academic background includes a BSc and PhD in Biochemistry with a focus on Experimental Chemotherapy from The University of Manchester, earned between 1977 and 1983.
This person is not in the org chart
This person is not in any offices
Spirea
Spirea Limited is a Cambridge-based company created to advance a new generation of antibody-targeted cancer treatments with significantly better efficacy and safety profiles. Spirea will use its innovative technology to enable a pipeline of superior and differentiated antibody drug conjugates for the treatment of a range of solid tumours.